Cancer cells have the extraordinary evolutionary potential to adapt and acquire resistance to most conventional and targeted therapies. In a new study, Lin et al., develop a systematic approach to identify combination therapies that produce cancer traps, in which evading the first drug makes the cancer vulnerable to the second.
In addition to self isolation, widespread testing to identify asymptomatic spreaders is needed. YaleNews:
The conclusion of a new Yale-led study is clear: Without dramatic action, there won’t be enough beds for the sickest COVID-19 patients.
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier B.V. or its licensors or contributors. ScienceDirect ® is a registered trademark of Elsevier B.V.
ScienceDirect ® is a registered trademark of Elsevier B.V.
An international team led by University of British Columbia researcher Dr. Josef Penninger has found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts.
The findings, published today in Cell, hold promise as a treatment capable of stopping early infection of the novel coronavirus that, as of April 2, has affected more than 981,000 people and claimed the lives of 50,000 people worldwide.
Shared by Michael Michalchik
Ivermectin is an inhibitor of the COVID-19 causative virus (SARS-CoV-2) in vitro.
• A single treatment able to effect ∼5000-fold reduction in virus at 48h in cell culture.
The U.S. Food and Drug Administration (FDA) approved the first blood test that looks for the antibodies against the novel coronavirus that causes COVID-19. This is different than assays that test for presence of the virus—those test to determine if a patient has COVID-19. These new antibody tests determine if the person was exposed to the virus, had COVID-19 and recovered. And it suggests, if positive, that the person is now immune to COVID-19 and can’t get it again.
Research Triangle Park, North Carolina-based Cellex was granted an emergency use authorization (EUA) on its test yesterday.
The test is performed on a blood sample taken from a patient’s vein and can be performed by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), the Health and Human Services division that oversees clinical diagnostic testing in the United States.
This is the first reported case of COVID-19–associated acute necrotizing hemorrhagic encephalopathy. As the number of patients with COVID-19 increases worldwide, clinicians and radiologists should be watching for this presentation among patients presenting with COVID-19 and altered mental status.
Home Radiology Recently Published PreviousNext Reviews and CommentaryFree AccessImages in Radiology COVID-19–associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI FeaturesNeo Poyiadji, Gassan Shahin, Daniel Noujaim, Michael Stone, Suresh Patel, Brent Griffith Neo Poyiadji, Gassan S…
Dr. Susan White and her genetics team treated two triplets from a family who had an undiagnosed neurodegenerative disorder in 2014. After one year of age, the children’s developmental skills declined. They lost visual coordination. Feeding and swallowing food became impossible. The children developed intractable seizures.
Exactly what led to their neurodegeneration was a mystery.
“As you can imagine, that was just a horrendous experience for their family and we suspected a genetic condition because of that pattern of problems occurring in both children,” White, an associate professor at Murdoch Children’s Research Institute (MCRI) and Victorian Clinical Genetics Services (VCGS), said in an interview with Being Patient.
The President says we are at war with the coronavirus. It’s a war we should fight to win.
The economy is in the tank, and anywhere from thousands to more than a million American lives are in jeopardy. Most analyses of options and trade-offs assume that both the pandemic and the economic setback must play out over a period of many months for the pandemic and even longer for economic recovery. However, as the economists would say, there is a dominant option, one that simultaneously limits fatalities and gets the economy cranking again in a sustainable way.
That choice begins with a forceful, focused campaign to eradicate Covid-19 in the United States. The aim is not to flatten the curve; the goal is to crush the curve. China did this in Wuhan. We can do it across this country in 10 weeks.
Please click the button below to report on a cancer patient with COVID-19. See below for eligibility.
